Favipiravir

Favipiravir

An anti-viral drug capable of inhibiting the RNA-dependent RNA polymerase (RdRp) of RNA viruses.

Favipiravir is an anti-viral drug capable of inhibiting the RNA-dependent RNA polymerase (RdRp) of RNA viruses. The official chemical name of Favipiravir is T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide. It was discovered by Toyama Chemical Co., Ltd during experiments held by the company for finding chemical compounds capable of exhibiting anti-viral activity against influenza viruses.

Anti-viral activity

Favipiravir must undergo phosphoribosylation inside of cells (intracellular) to become it's active form called favipiravir-RTP (favipiravir ribofuranosyl-5'-triphosphate). Research suggests Favipiravir exhibits a broad spectrum of anti-viral activity towards RNA viruses due to it's mechanism of action, and is effective for treating a wide range of types and sub-types of RNA influenza viruses, including strains typically showing resistance to anti-influenza drugs, which include: arenaviruses, bunyaviruses and filoviruses.

Mechanism of action

Favipiravir-RTP (the active form of Favipiravir) is able to become incorporated in viral RNA (vRNA), and may act as a binding agent on vRNA conserved polymerase domains which prevents the ability of vRNA to use the cellular machinery of its host organism required for its own replication and transcription. This mechanism of action is what is thought to give Favipiravir its anti-viral properties.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
November 26, 2020
clinicaltrials.gov
Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit - Full Text View.
Joe Pinkstone
October 28, 2020
Mail Online
A UCL-led study, dubbed the FLARE trial, will investigate the efficacy of favipiravir, which is used to treat the flu, and the cocktail of lopinavir/ritonavir which is given to HIV patients.
Sohini Das
July 22, 2020
@bsindia
Firm claims trial results showed 28.6% faster viral clearance in overall population, says drug well tolerated with no major side effects
Press Trust of India
June 26, 2020
@bsindia
The drugs are costly so the state has decided to buy them itself
June 24, 2020
Moneycontrol
Both companies have given a commitment to conduct clinical trials and submit data, following approval
SI Reporter
June 24, 2020
@bsindia
The stock has jumped 40 per cent in the intra-day trade on Monday after the firm received approval for Favipiravirs (Fabiflu), a potential Covid-19 drug, by the Drug Controller General of India
Press Trust of India
June 22, 2020
@bsindia
Glenmark Pharmaceuticals has launched the antiviral drug Favipiravir, while Cipla and Hetero have received approvals from the Drug Controller General of India to launch Remdesivir
SI Reporter
June 22, 2020
@bsindia
The company launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.
ANI
June 20, 2020
@bsindia
The domestic pharma giant announced the launch of the first oral Favipiravir in the brand name FabiFlu claiming that it is backed by strong clinical evidence
Agencies
June 2, 2020
@bsindia
Avifavir, described by its developers in Russia as perhaps the most promising anti-Covid-19 drug in the world, is derived from Favipiravir.
SI Reporter
May 15, 2020
@bsindia
Favipiravir is in various stages of clinical trials in many countries as an experimental treatment of Covid-19.
April 30, 2020
Firstpost
Stock market today LIVE Update: Sensex above 33,000, Nifty surges past 9,800-mark; RIL, HUL share prices gain ahead of Q4 results Watch LIVE News, Latest Updates, Live blog, Highlights and Live coverage online at firstpost.com.
SI Reporter
April 30, 2020
@bsindia
Glenmark is the first pharma company in India to be given an approval by the regulator to start the trial on COVID-19 patients
Samreen Ahmad
April 29, 2020
@bsindia
Company to apply to Indian Drug Authorities to start necessary studies and make the drug available to patients in the country expeditiously
SI Reporter
April 29, 2020
@bsindia
The drug has demonstrated positive outcomes, including a reduction in the duration of Covid-19 and improved lung conditions for the patients

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.